Literature DB >> 1892299

Methylprednisolone achieves greater concentrations in the lung than prednisolone. A pharmacokinetic analysis.

L S Greos1, P Vichyanond, D C Bloedow, C G Irvin, G L Larsen, S J Szefler, M R Hill.   

Abstract

Previous studies in humans and rabbits demonstrated that methylprednisolone appears in the lung in greater concentration than prednisolone. To ascertain which pharmacokinetic properties of these drugs explain this difference, we gave methylprednisolone and prednisolone, 5 mg/kg intravenous bolus, to 23 adult rabbits. To measure the plasma concentration versus time curves for methylprednisolone and prednisolone, samples were obtained predose through 480 min postdose. To measure the bronchoalveolar lavage glucocorticoid concentration versus time curves, lavage was performed once per experiment at seven separate time points from 5 to 480 min post-dose (two to four experiments per time point). Bronchoalveolar lavage fluid (BALF) recovery ranged from 50 to 75% and was similar in both groups. Glucocorticoid concentration in plasma and BALF was determined by high performance liquid chromatography. To normalize for the dilutional effects of lavage, epithelial lining fluid (ELF) recovery was quantitated from BALF volume and BALF and plasma urea concentrations. Pharmacokinetic parameters of the two glucocorticoids were calculated both noncompartmentally and by a three-compartment model. The extrapolated plasma glucocorticoid concentrations at time zero of methylprednisolone and prednisolone are similar, but the volume of distribution and plasma half-life of methylprednisolone are significantly greater than those of prednisolone (p less than 0.05). Although the clearance of the two drugs are not significantly different, methylprednisolone appears to have a slower Cl than prednisolone. The mean residence time (the average time drug remained in body) was significantly longer for methylprednisolone than for prednisolone (p less than 0.05), and plasma glucocorticoid concentrations became significantly different in the two groups by 90 min (p less than 0.05).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1892299     DOI: 10.1164/ajrccm/144.3_Pt_1.586

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  12 in total

1.  Effects of inhaled fluticasone and oral prednisolone on clinical and inflammatory parameters in patients with asthma.

Authors:  R J Meijer; H A Kerstjens; L R Arends; H F Kauffman; G H Koëter; D S Postma
Journal:  Thorax       Date:  1999-10       Impact factor: 9.139

Review 2.  Prolonged glucocorticoid treatment is associated with improved ARDS outcomes: analysis of individual patients' data from four randomized trials and trial-level meta-analysis of the updated literature.

Authors:  G Umberto Meduri; Lisa Bridges; Mei-Chiung Shih; Paul E Marik; Reed A C Siemieniuk; Mehmet Kocak
Journal:  Intensive Care Med       Date:  2015-10-27       Impact factor: 17.440

Review 3.  Childhood asthma--office management.

Authors:  M D Shah
Journal:  Indian J Pediatr       Date:  1996 Jan-Feb       Impact factor: 1.967

4.  Guidelines for the diagnosis and management of critical illness-related corticosteroid insufficiency (CIRCI) in critically ill patients (Part I): Society of Critical Care Medicine (SCCM) and European Society of Intensive Care Medicine (ESICM) 2017.

Authors:  Djillali Annane; Stephen M Pastores; Bram Rochwerg; Wiebke Arlt; Robert A Balk; Albertus Beishuizen; Josef Briegel; Joseph Carcillo; Mirjam Christ-Crain; Mark S Cooper; Paul E Marik; Gianfranco Umberto Meduri; Keith M Olsen; Sophia Rodgers; James A Russell; Greet Van den Berghe
Journal:  Intensive Care Med       Date:  2017-09-21       Impact factor: 17.440

Review 5.  Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids.

Authors:  David Czock; Frieder Keller; Franz Maximilian Rasche; Ulla Häussler
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

6.  Hydrocortisone treatment in early sepsis-associated acute respiratory distress syndrome: results of a randomized controlled trial.

Authors:  Surat Tongyoo; Chairat Permpikul; Wasineenart Mongkolpun; Veerapong Vattanavanit; Suthipol Udompanturak; Mehmet Kocak; G Umberto Meduri
Journal:  Crit Care       Date:  2016-10-15       Impact factor: 9.097

7.  Prolonged low-dose methylprednisolone treatment is highly effective in reducing duration of mechanical ventilation and mortality in patients with ARDS.

Authors:  Gianfranco Umberto Meduri; Reed A C Siemieniuk; Rachel A Ness; Samuel J Seyler
Journal:  J Intensive Care       Date:  2018-08-24

8.  Corticosteroid use in ARDS and its application to evolving therapeutics for coronavirus disease 2019 (COVID-19): A systematic review.

Authors:  Kaitlin M Landolf; Steven M Lemieux; Christina Rose; Jackie P Johnston; Christopher D Adams; Jerry Altshuler; Karen Berger; Deepali Dixit; Muhammad K Effendi; Mojdeh S Heavner; Diana Lemieux; Audrey J Littlefield; Andrea M Nei; Kent A Owusu; Marisa Rinehart; Blake Robbins; Ginger E Rouse; Melissa L Thompson Bastin
Journal:  Pharmacotherapy       Date:  2021-10-28       Impact factor: 6.251

Review 9. 

Authors:  Julien Malarewicz; Romain Kirchacker; Djillali Annane
Journal:  Prat Anesth Reanim       Date:  2008-01-03

Review 10.  General Adaptation in Critical Illness: Glucocorticoid Receptor-alpha Master Regulator of Homeostatic Corrections.

Authors:  Gianfranco Umberto Meduri; George P Chrousos
Journal:  Front Endocrinol (Lausanne)       Date:  2020-04-22       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.